FY2024 EPS Estimates for OPKO Health, Inc. (NASDAQ:OPK) Lowered by Barrington Research

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Equities researchers at Barrington Research decreased their FY2024 earnings per share (EPS) estimates for shares of OPKO Health in a research note issued to investors on Wednesday, May 8th. Barrington Research analyst M. Petusky now anticipates that the biotechnology company will earn ($0.34) per share for the year, down from their prior forecast of ($0.29). Barrington Research currently has a "Outperform" rating and a $1.50 target price on the stock. The consensus estimate for OPKO Health's current full-year earnings is ($0.33) per share. Barrington Research also issued estimates for OPKO Health's Q4 2024 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.22) EPS, FY2026 earnings at ($0.16) EPS, FY2027 earnings at ($0.10) EPS and FY2028 earnings at ($0.02) EPS.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.03). OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The firm had revenue of $173.70 million during the quarter, compared to analyst estimates of $182.99 million. During the same period in the prior year, the business earned ($0.02) EPS. The business's revenue for the quarter was down 26.9% compared to the same quarter last year.

A number of other equities analysts have also recently commented on the company. StockNews.com cut OPKO Health from a "hold" rating to a "sell" rating in a report on Friday, March 1st. HC Wainwright restated a "buy" rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $5.00 target price on shares of OPKO Health in a research report on Monday, April 1st.

OPKO Health Stock Up 1.6 %

Shares of OPK traded up $0.02 during midday trading on Friday, hitting $1.28. The stock had a trading volume of 2,103,231 shares, compared to its average volume of 12,110,228. The firm has a market cap of $892.15 million, a price-to-earnings ratio of -5.04 and a beta of 1.81. The company has a 50 day simple moving average of $1.15 and a two-hundred day simple moving average of $1.22. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.55 and a quick ratio of 1.22. OPKO Health has a twelve month low of $0.85 and a twelve month high of $2.24.

Hedge Funds Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently bought and sold shares of OPK. IPG Investment Advisors LLC acquired a new position in OPKO Health in the fourth quarter valued at $30,000. SlateStone Wealth LLC acquired a new position in shares of OPKO Health during the first quarter valued at about $31,000. River Wealth Advisors LLC bought a new stake in shares of OPKO Health during the third quarter worth about $38,000. Moseley Investment Management Inc. bought a new stake in shares of OPKO Health during the first quarter worth about $41,000. Finally, Northstar Group Inc. bought a new stake in shares of OPKO Health during the fourth quarter worth about $42,000. Institutional investors and hedge funds own 64.63% of the company's stock.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost bought 500,000 shares of the firm's stock in a transaction on Monday, March 18th. The shares were purchased at an average price of $0.87 per share, with a total value of $435,000.00. Following the completion of the purchase, the chief executive officer now owns 210,968,225 shares in the company, valued at approximately $183,542,355.75. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last quarter, insiders have purchased 3,100,000 shares of company stock valued at $2,923,000. 47.26% of the stock is currently owned by insiders.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.